Our latest deal : Domain Therapeutics raises $42M series A
by Jean-Alexandre Kaminisky, 2021-03-16 MyPL wins €1.1 Million European Union grant as part of Horizon Europe 2020 GerOnTe[1] project out of a
A major step and a critical milestone achieved prior to First In Human clinical trials FineHeart’s TET is a system
– SoniVie Acquires New Intellectual Property and Other Assets from Cardiosonic Moving TIVUS into New Therapeutic Areas Beyond Pulmonary Hypertension
French-Canadian biotech company has nominated DT-9081 as development candidate and launched CMC activities • DT-9081 will be combined with immune
Paris, November 23, 2020 – PKvitality, a French company specialized in bio wearables, has been rewarded by being named the
– International study designed to build on positive 12-month data from TROPHY1 demonstrating improvement in multiple clinical endpoints and no
Acticor Biotech Announces the Completion of Enrollment in ACTIMIS, its Key Phase 1b/2a Safety Study
Paris, July 1st, 2021 – Acticor Biotech, a clinical stage biotechnology company involved in the acute phase of thrombotic diseases,
Towards a new standard for device indication: Implantation for temporary or permanent use • Easy removal with a beating heart
Karista invests in MyPL increasing its financing to €1.8m & accelerating its development
by Jean-Alexandre Kaminisky, 2021-03-18 Karista invests in MyPL increasing its financing to €1.8m & accelerating its development Paris – France, March
Latest Insights
by Jean-Alexandre Kaminisky, 2021-03-18 Karista invests in MyPL increasing its financing to €1.8m & accelerating its development Paris – France, March
Paris, January 7th, 2020 – PKvitality, a French company specialized in bio wearables, has signed an agreement with Beurer GmBH,
Overall demand totaling €14.7 million, 1.24 times the offering The funds raised will be used to implement the strategy of
This press release may not be published, forwarded or distributed, directly or indirectly in the United States of America, Canada,
– International study designed to build on positive 12-month data from TROPHY1 demonstrating improvement in multiple clinical endpoints and no